The
following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net
loss per share because to do so would be anti-dilutive:
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share
| | |
2025 | | |
2024 | |
| | |
As of September 30, | |
| | |
2025 | | |
2024 | |
| Warrants [1] | |
| 6,911,773 | | |
| 928,593 | |
| Options | |
| 387,424 | | |
| 9,639 | |
| Series A Convertible Preferred Stock | |
| 72 | | |
| 72 | |
| Series B Convertible Preferred Stock | |
| 2,067 | | |
| 2,067 | |
| Total potentially dilutive shares | |
| 7,301,336 | | |
| 940,371 | |
| [1] | | As part of the
InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain
milestones and, accordingly, are not included in the amount currently reported. |
|